Global variation in the prevalence of elevated cholesterol in outpatients with established vascular disease or 3 cardiovascular risk factors according to national indices of economic development and health system performance

Circulation

Volumn 125, Issue 15, 2012, Pages 1858-1869

  Venkitachalam, Lakshmi ^a   Wang, Kaijun ^b   Porath, Avi ^c   Corbalan, Ramon ^d   Hirsch, Alan T ^e   Cohen, David J ^a,b   Smith, Sidney C ^f   Ohman, E Magnus ^g   Steg, Ph Gabriel ^h   Bhatt, Deepak L ⁱ   Magnuson, Elizabeth A ^a,b  

^a UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

^b SAINT LUKE S MID AMERICA HEART INSTITUTE   (United States)

^c BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^d PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^e UNIVERSITY OF MINNESOTA   (United States)

^f UNIVERSITY OF NORTH CAROLINA   (United States)

^g DUKE UNIVERSITY MEDICAL CENTER   (United States)

^h INSERM   (France)

ⁱ HARVARD MEDICAL SCHOOL   (United States)

Author keywords

cardiovascular disease; global trends; health system performance; hypercholesterolemia; national health expenditures

Indexed keywords

CHOLESTEROL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; ECONOMIC DEVELOPMENT; FEMALE; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HUMAN; HYPERLIPIDEMIA; INCOME; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PHASE 3 CLINICAL TRIAL; PREVALENCE; PRIORITY JOURNAL; VASCULAR DISEASE; WORLD HEALTH ORGANIZATION;

AGED; CARDIOVASCULAR DISEASES; CHOLESTEROL; DELIVERY OF HEALTH CARE; FEMALE; HEALTH EXPENDITURES; HEALTH POLICY; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; OUTPATIENTS; PREVALENCE; RISK FACTORS; VASCULAR DISEASES;

EID: 84859746998     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.111.064378     Document Type: Article

References (38)

1. World Health Organization (WHO). 2008-2013 Action Plan for the Global Strategy for the Prevention and Control of Noncommunicable Diseases: Prevent and Control Cardiovascular Diseases, Cancers, Chronic Respiratory Diseases and Diabetes. Geneva, Switzerland: WHO, 2008. http://whqlibdoc.who.int/publications/ 2009/9789241597418-eng.pdf. Accessed April 13, 2011.
2. World Health Organization (WHO). Cardiovascular Diseases (CVDs). Fact Sheet No. 317. Geneva, Switzerland: WHO; 2011. http://www.who.int/mediacentre/ factsheets/fs317/en/print.html. Accessed April 13, 2011.
3. Fuster V, Kelly BB, Vedanthan R. Promoting global cardiovascular health: moving forward. Circulation. 2011;123:1671-1678.
4. World Health Organization (WHO). The World Health Report 2002: Reducing Risks, Promoting Healthy Life. Geneva, Switzerland: WHO, 2002. http://www.who.int/whr/2002/en/whr02-en.pdf. Accessed April 12, 2011.
5. National Cholesterol Education Program (NCEP) Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002; 106, 3143-3421.
6. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, Ebrahim S, Faergeman O, Graham I, Mancia G, Cats VM, Orth-Gomer K, Perk J, Pyorala K, Rodicio J, Sans S, Sansoy V, Sechtem U, Silber S, Thomsen T, Wood D, Albus C, Bages N, Burell G, Conroy R, Christian Deter H, Hermann-Lingen C, Humphries S, Fitzgerald A, Oldenburg B, Schneiderman N, Uutela A, Williams R, Yarnell J, Priori SG, Angeles Alonso Garcia M, Blanc J-J, Budaj A, Cowie M, Dean V, Deckers J, Fernã ndez Burgos E, Lekakis J, Lindahl B, Mazzotta G, McGregor K, Morais Jo, Oto A, Smiseth O, Trappe H-J, Budaj A, Agardh C-D, Bassand J-P, Deckers J, Godycki-Cwirko M, Heagerty A, Heine R, Home P, Priori S, Puska P, Rayner M, Rosengren A, Sammut M, Shepherd J, Siegrist J, Simoons M, Tendera M, Zanchetti A. European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2003;24:1601-1610.
7. Tolonen H, Keil U, Ferrario M, Evans A; WHO MONICA Project. Prevalence, awareness and treatment of hypercholesterolaemia in 32 populations: results from the WHO MONICA Project. Int J Epidemiol. 2005;34:181-192.
8. Wood DA. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. Lancet. 2001;357: 995-1001.
9. Bhatt DL, Steg PG, Ohman EM, Hirsch AT, Ikeda Y, Mas JL, Goto S, Liau CS, Richard AJ, Rother J, Wilson PW. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA. 2006;295:180-189.
10. Kotseva K, Wood D, De Backer G, De Bacquer D, Pyörälä K, Keil U. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet. 2009;373:929-940.
11. Roth GA, Fihn SD, Mokdad AH, Aekplakorn W, Hasegawa T, Lim SS. High total serum cholesterol, medication coverage and therapeutic control: an analysis of national health examination survey data from eight countries. Bull World Health Organ. 2011;89:92-101.
12. Cacoub PP, Abola MTB, Baumgartner I, Bhatt DL, Creager MA, Liau C-S, Goto S, Rãther J, Steg PG, Hirsch AT. Cardiovascular risk factor control and outcomes in peripheral artery disease patients in the Reduction of Atherothrombosis for Continued Health (REACH) Registry. Atherosclerosis. 2009;204:e86-e92.
13. Kumar A, Fonarow GC, Eagle KA, Hirsch AT, Califf RM, Alberts MJ, Boden WE, Steg PG, Shao M, Bhatt DL, Cannon CP, on behalf of the REACH Investigators. Regional and practice variation in adherence to guideline recommendations for secondary and primary prevention among outpatients with atherothrombosis or risk factors in the United States: a report from the REACH Registry. Crit Pathw Cardiol. 2009;8:104-111.
14. Arnold SV, Spertus JA, Tang F, Krumholz HM, Borden WB, Farmer SA, Ting HH, Chan PS. Statin use in outpatients with obstructive coronary artery disease. Circulation. 2011;124:2405-2410.
15. Ohman EM, Bhatt DL, Steg PG, Goto S, Hirsch AT, Liau C-S, Mas J-L, Richard A-J, Röther J, Wilson PWF. The REduction of Atherothrombosis for Continued Health (REACH) Registry: an international, prospective, observational investigation in subjects at risk for atherothrombotic events-study design. Am Heart J. 2006;151:786.e1-e10.
16. World Health Organization (WHO). The World Health Report 2004: Changing History. Geneva, Switzerland: WHO, 2004. Accessed April 12, 2011.
17. World Bank. September 2004. World Development Indicators. http://data. worldbank.org/indicator. Accessed April 21, 2011.
18. World Health Organization (WHO). The World Health Report 2000: Health Systems: Improving Performance. Geneva, Switzerland: WHO, 2000. http://www.who.int/whr/2000/en/whr00-en.pdf. Accessed May 26, 2011.
19. Food and Agricultural Organization of the United Nations. http://faostat. fao.org/site/345/default.aspx. Accessed April 21, 2009.
20. Hedekar D. Multilevel models for ordinal and nominal variables. In: de Leeuw J, Meijer E, eds. Handbook of Multilevel Analysis. New York, NY: Springer; 2008:239-275.
21. Orlandini A, Diaz R, Wojdyla D, Pieper K, Van de Werf F, Granger CB, Harrington RA, Boersma E, Califf RM, Armstrong P, White H, Simes J, Paolasso E. Outcomes of patients in clinical trials with ST-segment elevation myocardial infarction among countries with different gross national incomes. Eur Heart J. 2006;27:527-533.
22. Steg PG, Bhatt DL, Wilson PWF, D'Agostino R Sr, Ohman EM, Rother J, Liau C-S, Hirsch AT, Mas J-L, Ikeda Y, Pencina MJ, Goto S, for the REACH Registry Investigators. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA. 2007;297:1197-1206.
23. Alberts MJ, Bhatt DL, Mas JL, Ohman EM, Hirsch AT, Rother J, Salette G, Goto S, Smith SC Jr, Liau CS, Wilson PW, Steg PG. Three-year follow-up and event rates in the international REduction of Athero-thrombosis for Continued Health Registry. Eur Heart J. 2009;30: 2318-2326.
24. Cacoub PP, Zeymer U, Limbourg T, Baumgartner I, Poldermans D, Rother J, Bhatt DL, Steg PG. Effects of adherence to guidelines for the control of major cardiovascular risk factors on outcomes in the REduction of Atherothrombosis for Continued Health (REACH) Registry Europe. Heart. 2011;97:660-667.
25. Kotseva K, Stagmo M, De Bacquer D, De Backer G, Wood D. Treatment potential for cholesterol management in patients with coronary heart disease in 15 European countries: findings from the EUROASPIRE II survey. Atherosclerosis. 2008;197:710-717.
26. Yusuf S, Islam S, Chow CK, Rangarajan S, Dagenais G, Diaz R, Gupta R, Kelishadi R, Iqbal R, Avezum A, Kruger A, Kutty R, Lanas F, Lisheng L, Wei L, Lopez-Jaramillo P, Oguz A, Rahman O, Swidan H, Yusoff K, Zatonski W, Rosengren A, Teo KK. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet. 2011;378:1231-1243.
27. Ferket BS, Colkesen EB, Visser JJ, Spronk S, Kraaijenhagen RA, Steyerberg EW, Hunink MGM. Systematic review of guidelines on cardiovascular risk assessment: which recommendations should clinicians follow for a cardiovascular health check? Arch Intern Med. 2011;170:27-40.
28. World Health Organization (WHO). Prevention of Cardiovascular Disease: Guidelines for Assessment and Management of Total Cardiovascular Risk. Geneva, Switzerland: WHO; 2007. http://www.who.int/cardiovascular- diseases/guidelines/ Full%20text.pdf. Accessed November 7, 2011.
29. Mendis S, Fukino K, Cameron A, Laing R, Filipe A, Khatib O, Leowski J, Ewen M. The availability and affordability of selected essential medicines for chronic diseases in six low-and middle-income countries. Bull World Health Organ. 2007;85:279-288.
30. Cameron A, Ewen M, Ross-Degnan D, Ball D, Laing R. Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis. Lancet. 2009;373:240-249.
31. van Mourik M, Cameron A, Ewen M, Laing R. Availability, price and affordability of cardiovascular medicines: a comparison across 36 countries using WHO/HAI data. BMC Cardiovasc Disord. 2010;10:25.
32. Choudhry NK, Avorn J, Glynn RJ, Antman EM, Schneeweiss S, Toscano M, Reisman L, Fernandes J, Spettell C, Lee JL, Levin R, Brennan T, Shrank WH. Full coverage for preventive medications after myocardial infarction. N Engl J Med. 2011;365:2088-2097.
33. Elinder LSf. Obesity, hunger, and agriculture: the damaging role of subsidies. BMJ. 2005;331:1333-1336.
34. Almeida C, Braveman P, Gold MR, Szwarcwald CL, Ribeiro JM, Miglionico A, Millar JS, Porto S, Costa NdR, Rubio VO, Segall M, Starfield B, Travassos C, Uga A, Valente J, Viacava F. Methodological concerns and recommendations on policy consequences of the World Health Report 2000. Lancet. 2001;357:1692-1697.
35. Richardson J, Wildman J, Robertson IK. A critique of the World Health Organisation's evaluation of health system performance. Health Econ. 2003;12:355-366.
36. World Health Organization (WHO). Global Status Report on Noncom-municable Diseases, 2010. Geneva, Switzerland: WHO, 2011. http://whqlibdoc.who.int/ publications/2011/9789240686458-eng.pdf. Accessed July 5, 2011.
37. Ockene JK, Schneider KL, Lemon SC, Ockene IS. Can we improve adherence to preventive therapies for cardiovascular health? Circulation. 2011;124:1276-1282.
38. Frieden TR, Berwick DM. The "Million Hearts" initiative\preventing heart attacks and strokes. N Engl J Med. 2011;365:e27.